| Date Filed | Type | Description |
| 08/11/2023 |
4
| Azelby Robert (Director) has filed a Form 4 on CHINOOK THERAPEUTICS, INC.|
Txns:
| Disposed/sold 28,200 options to buy
@ $21.6, valued at
$609.1k
Disposed/sold 7,000 restricted stock units
@ $0 |
|
| 11/02/2022 |
4
| Azelby Robert (President & CEO) has filed a Form 4 on Eliem Therapeutics, Inc.|
Txns:
| Granted 500,000 options to buy
@ $3.27, valued at
$1.6M
|
|
| 01/31/2022 |
4
| Azelby Robert (President & CEO) has filed a Form 4 on Eliem Therapeutics, Inc.|
Txns:
| Granted 500,000 options to buy
@ $8.21, valued at
$4.1M
|
|
| 08/09/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 06/11/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/23/2020 |
4
| Azelby Robert (Director) has filed a Form 4 on IMMUNOMEDICS INC|
Txns:
| Disposed/sold 29,040 options to buy
@ $0
Disposed/sold 3,718 restricted stock units
@ $0 |
|
| 06/22/2020 |
4
| Azelby Robert (Director) has filed a Form 4 on IMMUNOMEDICS INC|
Txns:
| Granted 3,718 shares
@ $0
Granted 6,540 options to buy
@ $33.62, valued at
$219.9k
|
|
| 06/05/2020 |
4
| Azelby Robert (Director) has filed a Form 4 on Clovis Oncology, Inc.|
Txns:
| Granted 40,138 options to buy
@ $6.48, valued at
$260.1k
|
|
| 02/27/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/27/2020 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/24/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/07/2019 |
4
| Azelby Robert (Director) has filed a Form 4 on Clovis Oncology, Inc.|
Txns:
| Granted 28,882 options to buy
@ $14.66, valued at
$423.4k
|
|
| 04/25/2019 |
4
| Azelby Robert (President and CEO) has filed a Form 4 on ALDER BIOPHARMACEUTICALS INC|
Txns:
| Granted 150,000 options to buy
@ $16.2, valued at
$2.4M
|
|
| 02/08/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/15/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/12/2018 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 06/15/2018 |
4
| Azelby Robert (President and CEO) has filed a Form 4 on ALDER BIOPHARMACEUTICALS INC|
Txns:
| Granted 1,000,000 options to buy
@ $16.2, valued at
$16.2M
|
|
| 06/15/2018 |
3
| Azelby Robert (President and CEO) has filed a Form 3 on ALDER BIOPHARMACEUTICALS INC |
| 03/13/2018 |
4
| Azelby Robert (Director) has filed a Form 4 on Cascadian Therapeutics, Inc.|
Txns:
| Disposed/sold 12,437 restricted stock units
@ $0
Disposed/sold 13,927 restricted stock units
@ $0 |
|
| 03/07/2018 |
4
| Azelby Robert (EVP & Chief Commercial Officer) has filed a Form 4 on Juno Therapeutics, Inc.|
Txns:
| Disposed/sold 7,500 shares
@ $0
Disposed/sold 20,580 shares
@ $0
Disposed/sold 25,639 shares
@ $0
Disposed/sold 35,893 shares
@ $0
Disposed/sold 93,294 options to buy
@ $51.76, valued at
$4.8M
Disposed/sold 30,002 options to buy
@ $25.29, valued at
$758.8k
Disposed/sold 98,545 options to buy
@ $20.76, valued at
$2M
|
|
| 02/15/2018 |
4/A
| Azelby Robert (EVP & Chief Commercial Officer) has filed a Form 4 on Juno Therapeutics, Inc.|
Txns:
| Sold 4,159 shares
@ $85.55, valued at
$355.8k
|
|
| 02/14/2018 |
4
| Azelby Robert (EVP & Chief Commercial Officer) has filed a Form 4 on Juno Therapeutics, Inc.|
Txns:
| Sold 4,157 shares
@ $85.55, valued at
$355.6k
|
|
| 02/09/2018 |
4
| Azelby Robert (EVP & Chief Commercial Officer) has filed a Form 4 on Juno Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 2,700 shares
@ $85.49, valued at
$230.8k
Sold 3,497 shares
@ $85.77, valued at
$299.9k
Exercised 834 options to buy
@ $25.29, valued at
$21.1k
Exercised 2,663 options to buy
@ $20.76, valued at
$55.3k
|
|
| 02/02/2018 |
4
| Azelby Robert (EVP & Chief Commercial Officer) has filed a Form 4 on Juno Therapeutics, Inc.|
Txns:
| Granted 25,639 shares
@ $0
Sold 4,167 shares
@ $85.78, valued at
$357.4k
Exercised 4,167 options to buy
@ $51.76, valued at
$215.7k
|
|
| 01/24/2018 |
4
| Azelby Robert (EVP & Chief Commercial Officer) has filed a Form 4 on Juno Therapeutics, Inc.|
Txns:
| Sold 102,539 shares
@ $86.25, valued at
$8.8M
Exercised 102,539 options to buy
@ $51.76, valued at
$5.3M
|
|
| 01/19/2018 |
4
| Azelby Robert (EVP & Chief Commercial Officer) has filed a Form 4 on Juno Therapeutics, Inc.|
Txns:
| Sold 21,141 shares
@ $68.1, valued at
$1.4M
Sold 7,990 shares
@ $69.95, valued at
$558.9k
Exercised 2,498 options to buy
@ $25.29, valued at
$63.2k
Exercised 26,633 options to buy
@ $20.76, valued at
$552.9k
|
|
| 12/20/2017 |
4
| Azelby Robert (EVP & Chief Commercial Officer) has filed a Form 4 on Juno Therapeutics, Inc.|
Txns:
| Sold 1,816 shares
@ $44.96, valued at
$81.6k
|
|
| 11/09/2017 |
4
| Azelby Robert (EVP & Chief Commercial Officer) has filed a Form 4 on Juno Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 684 shares
@ $55.98, valued at
$38.3k
|
|
| 11/03/2017 |
4
| Azelby Robert (EVP & Chief Commercial Officer) has filed a Form 4 on Juno Therapeutics, Inc.|
Txns:
| Sold 6,666 shares
@ $54.95, valued at
$366.3k
Exercised 6,666 options to buy
@ $25.29, valued at
$168.6k
|
|
| 10/20/2017 |
4
| Azelby Robert (EVP & Chief Commercial Officer) has filed a Form 4 on Juno Therapeutics, Inc.|
Txns:
| Granted 35,893 shares
@ $0 |
|
| 09/14/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/31/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/13/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 04/04/2017 |
4
| Azelby Robert (Director) has filed a Form 4 on Cascadian Therapeutics, Inc.|
Txns:
| Granted 12,437 restricted stock units
@ $0 |
|
|